Abstract
Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.
Original language | English |
---|---|
Journal | Journal of Clinical Endocrinology and Metabolism |
Volume | 92 |
Issue number | 5 |
Pages (from-to) | 1769-72 |
Number of pages | 4 |
ISSN | 0021-972X |
DOIs | |
Publication status | Published - 1 May 2007 |